PPARs have α, β, γ, and δ subtypes, among which, highly expressed PPARα has been recognized to mitigate NAFLD by enhancing lipid metabolism and may affect the editing of apo B mRNA [16, 17]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.